|
|
|
|
Vol. 11, Issue 7, 2235-2249, July 2000
1C and
1A
Integrin Cytoplasmic Variants in Modulating Focal Adhesion
Kinase, Protein Kinase B/AKT, and Ras/Mitogen-activated Protein Kinase
Pathways

Departments of *Pathology and
Pharmacology, Yale
University School of Medicine, New Haven, Connecticut 06520
| |
ABSTRACT |
|---|
|
|
|---|
The integrin cytoplasmic domain modulates cell
proliferation, adhesion, migration, and intracellular signaling. The
1 integrin subunits,
1C and
1A, that contain variant cytoplasmic domains differentially affect cell proliferation;
1C inhibits
proliferation, whereas
1A promotes it. We investigated
the ability of
1C and
1A to modulate
integrin-mediated signaling events that affect cell
proliferation and survival in Chinese hamster ovary stable cell lines
expressing either human
1C or human
1A.
The different cytodomains of either
1C or
1A did not affect either association with the endogenous
2,
V, and
5 subunits or
cell adhesion to fibronectin or TS2/16, a mAb to human
1. Upon engagement of endogenous and exogenous
integrins by fibronectin, cells expressing
1C
showed significantly inhibited extracellular signal-regulated kinase (ERK) 2 activation compared with
1A stable cell lines.
In contrast, focal adhesion kinase phosphorylation and Protein
Kinase B/AKT activity were not affected. Selective engagement of the
exogenously expressed
1C by TS2/16 led to stimulation of
Protein Kinase B/AKT phosphorylation but not of ERK2 activation; in
contrast,
1A engagement induced activation of both
proteins. We show that Ras activation was strongly reduced in
1C stable cell lines in response to fibronectin adhesion
and that expression of constitutively active Ras, Ras 61 (L), rescued
1C-mediated down-regulation of ERK2 activation. Inhibition of cell proliferation in
1C stable cell lines
was attributable to an inhibitory effect of
1C on the
Ras/MAP kinase pathway because expression of activated MAPK
kinase rescued
1C antiproliferative effect. These
findings show that the
1C variant, by means of a unique
signaling mechanism, selectively inhibits the MAP kinase pathway
by preventing Ras activation without affecting either survival signals
stimulated by integrins or cellular interactions with the
extracellular matrix. These findings highlight a role for
1-specific cytodomain sequences in maintaining an
intracellular balance of proliferation and survival signals.
| |
INTRODUCTION |
|---|
|
|
|---|
Integrins are a large family of heterodimeric
transmembrane receptors composed of
and
subunits (Hynes, 1992
).
In addition to their role as adhesion receptors, integrins have
been shown to regulate intracellular signaling pathways and cellular
functions such as cell migration, proliferation, and survival (Schwartz et al., 1995
; Bottazzi and Assoian, 1997
; Frisch and
Ruoslahti, 1997
).
It is well established that the cytoplasmic domain of the
subunit is required for integrins to modulate many cellular
functions and to trigger signaling events that result in protein
phosphorylation (Hemler et al., 1995
; Fornaro and Languino,
1997
; Wei et al., 1998
) and interactions with intracellular
proteins (Hemler, 1998
). Thus, mutations or deletions in the
1A subunit cytodomain have been shown to alter
the ability of this integrin to trigger focal adhesion kinase
(FAK) phosphorylation (Guan et al., 1991
) and to interact
with cytoskeletal proteins such as talin and filamin (Chen et
al., 1995
; Lewis and Schwartz, 1995
; Pfaff et al.,
1998
).
The identification and characterization of a number of spliced variants
of the integrin cytoplasmic domain in the
and
subgroups
(Fornaro and Languino, 1997
) have added a new level of complexity to
integrin functions. Four different
1
isoforms have been identified (
1A,
1B,
1C, and
1D) and have been shown to differentially
affect receptor localization, cell proliferation, cell adhesion and
migration, interactions with intracellular proteins, and ultimately
phosphorylation and activation of signaling molecules (Belkin et
al., 1997
; Fornaro and Languino, 1997
; Belkin and Retta, 1998
;
Pfaff et al., 1998
; Retta et al., 1998
; Meredith
et al., 1999
).
The
1C integrin is an alternatively
spliced variant of the
1 subfamily that
contains a unique 48-amino acid sequence in its cytoplasmic domain
(Languino and Ruoslahti, 1992
). We and others have shown that either
full-length
1C or its cytoplasmic domain
inhibits prostate cancer epithelial cell (Fornaro et al., 1998
; Meredith et al., 1999
), endothelial cell (Meredith
et al., 1999
), and fibroblast (Fornaro et al.,
1995
; Meredith et al., 1995
, 1999
) proliferation. In vivo,
1C is expressed in nonproliferative, differentiated epithelium and is selectively down-regulated in prostatic adenocarcinoma, and its expression inversely correlates with
markers of cell proliferation in breast carcinoma (Fornaro et
al., 1996
, 1998
, 1999
; Manzotti et al., 2000
). However,
the signaling pathways affected by
1C are
still unknown.
FAK is a nonreceptor protein tyrosine kinase that has been shown to
colocalize with integrins at focal contact sites (Guan et
al., 1991
). FAK becomes tyrosine phosphorylated in response to
integrin engagement (Guan et al., 1991
; Kornberg
et al., 1991
) and has been shown to prevent apoptosis
(Frisch et al., 1996
; Hungerford et al., 1996
; Xu
et al., 1996
; Illic et al., 1998
; Cary and Guan,
1999
). Two recent reports have highlighted a new role for FAK in the
modulation of cell cycle progression and in the inhibition of
integrin-stimulated signaling events during mitosis (Zhao
et al., 1998
; Yamakita et al.,
1999
). The first study showed that FAK
overexpression accelerates the G1/S phase transition, increases cyclin
D1 levels, and decreases p21waf1 expression (Zhao
et al., 1998
). The second study demonstrated that FAK
undergoes mitosis-specific serine phosphorylation accompanied by
tyrosine dephosphorylation, which results in FAK/Cas/c-Src complex
dissociation and inhibition of signal transduction pathways involving
integrins (Yamakita et al., 1999
).
In addition to stimulating FAK, integrins can also activate the
phosphatidylinositol 3-kinase (PI 3-kinase) pathway (Keely et
al., 1998
). PI 3-kinases are a family of lipid kinases activated by a wide variety of extracellular stimuli. The lipid products of PI
3-kinases, specifically
phosphatidylinositol(3,4)biphosphate and
phosphatidylinositol(3,4,5)triphosphate, affect
cell proliferation, survival, differentiation, and migration by
targeting specific signaling molecules such as the serine/threonine
protein kinase B, also known as AKT, and PKC (Jiang et
al., 1999
; Rameh and Cantley, 1999
). Integrin-mediated
adhesion to the extracellular matrix stimulates the production of
phosphatidylinositol(3,4)biphosphate and
phosphatidylinositol(3,4,5)triphosphate (Khwaja
et al., 1997
; King et al., 1997
), the association
of the p85 PI 3-kinase subunit with FAK (Chen and Guan, 1994
), and AKT
activation (Khwaja et al., 1997
; King et al.,
1997
). AKT plays an important role in transducing survival signals in
response to several growth factors and integrin engagement
(Khwaja et al., 1997
; Downward, 1998
).
The small GTPase Ras is a critical component of signaling
pathways that control cell proliferation, differentiation, and survival (Campbell et al., 1998
; Rebollo and Martinez-A, 1999
). The
Ras/extracellular signal-regulated kinase (ERK) 1 and 2/MAP kinase
pathway plays a pivotal role in modulating gene expression and cell
cycle progression in response to mitogens (Robinson and Cobb, 1997
;
Guadagno and Ferrell, 1998
; Brunet et al., 1999
).
Integrin clustering has been shown to stimulate Ras GTP loading
(Clark and Hynes, 1996
; Wary et al., 1996
; King et
al., 1997
; Mainiero et al., 1997
; Miranti et
al., 1999
) and to activate specific effectors of the Ras/MAP kinase signaling cascade such as Raf-1 and MAPK kinase (MEK) (Howe et al., 1998
; Schlaepfer and Hunter, 1998
). In several
studies, the dominant negative N17 mutant of Ras has been shown to
block extracellular matrix-mediated ERK2 activation (Clark and Hynes, 1996
; Wary et al., 1996
; King et al., 1997
;
Mainiero et al., 1997
; Schlaepfer and Hunter, 1997
; Wei
et al., 1998
), whereas in one report it had no effect (Chen
et al., 1996b
). The mechanisms of integrin-mediated
activation of the MAP kinase cascade comprise three models (Howe
et al., 1998
). Two models include Src family kinases and Ras
as critical links between integrin-mediated adhesion and MAP
kinase activation. In the first model, integrin ligation leads
to Src and FAK activation, Grb2 binding to FAK, and membrane localization of the guanine nucleotide exchange factor Sos, which then
promotes Ras activation (Schlaepfer et al., 1994
, 1998
). In
the second model, integrins activate the Ras/MAP kinase pathway via the tyrosine kinase Fyn and the adaptor protein Shc (Wary et
al., 1996
, 1998
). A recent report has indicated that
fibronectin-induced PKC activation plays a role in ERK2 activation
upstream of Shc (Miranti et al., 1999
). The third model
proposes a Ras-independent activation of Raf and, thus, ERK2 by
integrins (Chen et al., 1996b
; Lin et
al., 1997
).
Using Chinese hamster ovary (CHO) stable cell lines expressing
either human
1C or human
1A, we have analyzed the ability of
1C and
1A to modulate
signaling pathways that control cell proliferation and survival. The
1C variant associates with the same
subunits as
1A and does not affect cell
adhesion to
1 ligands. We show that
1C has an inhibitory effect on ERK2 activation mediated by fibronectin without affecting FAK phosphorylation and AKT
activity. We also show that Ras activation stimulated by adhesion to
fibronectin is inhibited in
1C transfectants
and that constitutively active Ras and MEK rescue
1C-mediated down-regulation of ERK2 activation
and inhibition of cell growth, respectively. This is the first
description of a selective inhibitory role of the integrin
cytoplasmic domain on the Ras/MAP kinase pathway. Moreover, AKT
phosphorylation is observed in response to antibody-mediated engagement
of human
1C and
1A,
and ERK2 activation is supported by
1A but not
by
1C ligation, indicating a different role
for
1 variants in the activation of AKT and
MAP kinase pathways. We suggest that by expressing variant
1 intracellular domains, cells may accomplish
the delicate task of inhibiting proliferation without affecting either
selective downstream survival signals (FAK and AKT) mediated by
integrins or interactions with the extracellular environment.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Reagents and Antibodies
Rabbit antibodies specific for the
1C
subunit cytoplasmic domain were affinity-purified as described
previously (Fornaro et al., 1996
). The following antibodies
were used: mouse mAbs P4C10 and TS2/16 to human
1 integrin (Life Technologies,
Gaithersburg, MD, and American Type Culture Collection, Rockville, MD,
respectively), 7E2 to hamster
1
integrin, PB1 to hamster
5
1 (a kind gift of Dr. R.L. Juliano, University of North Carolina, Chapel Hill, NC), E10
to phospho-ERK1 and 2 (New England Biolabs, Beverly, MA), 12CA5 to
hemagglutinin (Boehringer Mannheim, Indianapolis, IN), and to
pan Ras (Transduction Laboratories, Lexington, KY); rabbit affinity-purified antibodies to FAK Y397
(Biosource International, Camarillo, CA), to AKT (New England Biolabs),
and to FAK and ERK1 and 2 (Santa Cruz Biotechnology, Santa Cruz, CA).
Rabbit antisera to
5,
v, or
4 were provided by Dr. E. Ruoslahti (The Burnham Institute, La Jolla, CA), antiserum to
2 was provided by Dr. M.E. Hemler (Dana-Farber
Cancer Institute, Boston, MA), and antiserum to
1C was described previously (Fornaro et
al., 1996
). Human plasma fibronectin and human vitronectin were
purified as described (Engvall and Ruoslahti, 1977
; Yatohgo et
al., 1988
). Poly-L-lysine and nonimmune
rabbit and mouse immunoglobulin G were purchased from Sigma Chemical
(St. Louis, MO).
Cells and Plasmids
To obtain stable cell lines expressing
1A in a tetracycline-regulated system,
ClaI-XbaI fragment encoding full-length human
1A was isolated from
Bluescript-
1A and subcloned into
ClaI-SpeI sites in the pTet-Splice plasmid (a
kind gift of Dr. D. Schatz, Yale University, New Haven, CT) to generate
the pTet-
1A construct. The
pTet-
1C construct has been described
previously (Fornaro et al., 1999
). CHO stable cell lines
expressing either human
1C (clones 16.4, 16.28, and 16.30) or human
1A (clones 10.2, 10.18, and 10.23) integrins under the control of a
tetracycline-regulated promoter were generated and maintained in growth
medium containing 1 µg/ml tetracycline (Boehringer Mannheim) and 0.1 mg/ml G418 (Life Technologies) as described (Fornaro et al.,
1999
).
pMLC-1 plasmids containing hemagglutinin-tagged wild-type MEK (MEK WT)
and constitutively active MEK (MEK EE) have been described previously
(Bennett and Tonks, 1997
). The pGEX-RBD plasmid encodes amino acids
1-149 of cRaf-1 fused to GST (Taylor and Shalloway, 1996
). The
pMT3-Ras 61 (L) encodes a c-rasH form containing
a codon 61 mutation (Bennett et al., 1996
).
1C-CHO stable cell lines were transiently
transfected by electroporation by using 10 µg of either MEK WT, MEK
EE, Ras 61 (L), or vector alone as described (Fornaro et
al., 1999
). Cells were incubated for 48 h at 37°C in growth
medium either in the absence or in the presence of 1 µg/ml
tetracycline and serum-starved during the last 24 h of the 48-h
culture before analysis of either cell proliferation or ERK2 activity
as described below.
Flow Cytometry
Surface expression of exogenous human
1C and
1A
integrins was achieved by withdrawal of tetracycline from the
growth medium; in both cell transfectants, maximal and comparable
1C or
1A expression
were consistently obtained 48 h after tetracycline removal. For
each experiment, exogenous human
1
integrin expression was monitored by FACS with TS2/16
serum-free culture supernatant or 12CA5 as negative control antibody
(Fornaro et al., 1999
). Endogenous hamster
1 or
5
1 integrin
expression was analyzed with either 5 µg/ml 7E2 or 1 µg/ml PB1,
respectively (Fornaro et al., 1995
).
Immunoprecipitation of
1C and
1A
Integrins
CHO stable cell lines were cultured for 48 h in the absence
of tetracycline to induce
1C or
1A integrin expression (Fornaro et al., 1999
). Cells were detached with 0.05% trypsin/0.53
mM EDTA (Life Technologies) and surface iodinated as described
previously (Bartfeld et al., 1993
). Cells were lysed in 1%
NP-40 (Calbiochem, La Jolla, CA), 0.5% sodium deoxycholate (Sigma),
0.1% SDS (American Bioanalytical, Natick, MA), 150 mM NaCl, 50 mM
Tris-HCl, pH 7.5, 1 mM PMSF (Life Technologies), 10 µg/ml aprotinin
(Sigma), 10 µg/ml leupeptin (Calbiochem), and 10 µg/ml pepstatin
(Sigma) for 30 min at 4°C.
1C and
1A integrins were immunoprecipitated
with P4C10 and protein A-Sepharose (Sigma) as described (Fornaro
et al., 1995
). Immunocomplexes were dissociated with 20 mM
Tris-HCl, pH 7.5, 2% SDS and boiled for 5 min. The dissociated
material was then diluted 10-fold with lysis buffer and reprecipitated overnight at 4°C with 30 µl of rabbit serum specific for the
1C subunit cytoplasmic domain.
Immunoprecipitates were recovered with protein A-Sepharose, washed
four times with lysis buffer, and resuspended in loading buffer (2%
SDS, 50 mM Tris-HCl, pH 6.8, 100 mM DTT [American Bioanalytical],
10% glycerol, and 0.1% bromphenol blue [Bio-Rad, Hercules, CA]).
Proteins were separated by SDS-PAGE (7.5%) and visualized by autoradiography.
Immunoprecipitations of
Subunits Associated with
1C
CHO stable cell lines were cultured for 72 h in the absence
of tetracycline; cells were then detached with 0.05% trypsin/0.53 mM
EDTA and surface iodinated as described above. Cells were lysed in 1%
Triton X-100 (American Bioanalytical), 150 mM NaCl, 20 mM Tris-HCl, pH
7.5, 1 mM MgCl2, 1 mM
CaCl2, 1 mM PMSF, 10 µg/ml aprotinin, and 10 µg/ml leupeptin for 30 min at 4°C.
1C and
1A integrins were immunoprecipitated
with P4C10 as described above. Immunoprecipitates were washed five
times with lysis buffer, resuspended in 10 mM Tris-HCl, pH 7.5, 0.5%
SDS, and incubated for 10 min at 70°C. The eluted material was
diluted threefold with lysis buffer and reprecipitated with rabbit
antiserum to
5,
V,
4, or
2 overnight at
4°C. Immunoprecipitates were recovered with protein A-Sepharose,
washed three times with lysis buffer, and resuspended in loading
buffer. Proteins were separated by SDS-PAGE (10%) and visualized by autoradiography.
Cell Adhesion Assay to
1 Ligands
Cell adhesion to fibronectin (10 µg/ml), 7E2 (1 µg/ml),
TS2/16 (1:10 dilution of culture supernatant), mouse immunoglobulin G
(1 µg/ml), and BSA (10 mg/ml; Sigma) was performed as described previously (Languino et al., 1993
) with 25,000 51Cr-labeled cells (51Cr
from DuPont-New England Nuclear, Wilmington, DE).
For analysis of FAK, AKT, and ERK2, CHO stable cell lines were cultured for 48 h either in the absence or in the presence of 1 µg/ml tetracycline, starved, and then detached as described above. Cells were held in suspension for 30-60 min at 37°C and either kept in suspension or plated on tissue culture plates coated with poly-L-lysine (5-10 µg/ml), fibronectin (10 µg/ml), TS2/16 (1:10 dilution of culture supernatant), or 7E2 (3 µg/ml) at 37°C for the indicated times. Where indicated, cells were incubated for 15 min at 37°C with 100 nM wortmannin (Calbiochem) before plating onto ligand-coated dishes. The cells were then washed twice with PBS (Life Technologies) and lysed in the appropriate ice-cold lysis buffer. The protein content in each lysate was quantitated with the bicinchoninic acid protein assay reagent (Pierce, Rockford, IL).
In all instances, quantification of immunoreactive bands was performed by densitometric analysis; the values are given as fold increase on fibronectin, TS2/16, or 7E2 versus poly-L-lysine or suspension within each established cell line after normalization for protein loading. The values from several experiments are reported as means ± SEM.
FAK Analysis
CHO stable cell lines were lysed with 1% NP-40, 0.5% deoxycholate, 50 mM HEPES, pH 7.5, 150 mM NaCl, 100 mM sodium fluoride (Sigma), 1 mM sodium vanadate (Sigma), 5 mM Na4P2O7 (J.T. Baker, Phillipsburg, NJ), 1 mM PMSF, 10 µg/ml aprotinin, and 10 µg/ml leupeptin for 30 min at 4°C, and insoluble material was removed by centrifugation at 14,000 × g for 15 min at 4°C.
FAK was immunoprecipitated from 500 µg of total cell lysate
with 0.5 µg of C-20, an affinity-purified antibody to FAK.
Immunocomplexes were collected with protein A-Sepharose, washed five
times with lysis buffer, and resuspended in loading buffer. Proteins
were separated by 10% SDS-PAGE, and FAK phosphorylation on
Tyr397 was analyzed by
immunoblotting with a rabbit affinity-purified antibody
that recognizes FAK only when phosphorylated on
Y397. FAK protein levels were analyzed by
immunoblotting with C-20 rabbit affinity-purified
antibody to FAK as described (Zheng et al., 1999
).
AKT Analysis
CHO stable cell lines were lysed with 1% NP-40, 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM EDTA, 50 mM sodium fluoride, 1 mM sodium vanadate, 1 mM Na4P2O7, 1 mM PMSF, 10 µg/ml aprotinin, and 10 µg/ml leupeptin for 30 min at 4°C. Analysis of AKT phosphorylation was performed by immunoblotting with phospho-specific antibody to Ser473 (New England Biolabs) according to the manufacturer's instructions.
AKT kinase activity was assayed according to Franke et al.
(1995)
. Briefly, 50 µg of detergent cell extracts were cleared by
centrifugation at 14,000 × g for 15 min at 4°C. AKT
was immunoprecipitated with 0.1 µg of affinity-purified antibody to
AKT. Immunocomplexes were collected with protein A-Sepharose and
washed three times with lysis buffer, once with 20 mM HEPES, pH
7.5, and once with kinase buffer (20 mM HEPES, pH 7.5, 1 mM DTT, 10 mM
MnCl2, 10 mM MgCl2). The
AKT kinase activity was assayed with kinase buffer containing 10 µCi
of [
-32P]ATP (3000 Ci/mmol; Amersham Life
Sciences, Arlington Heights, IL), 5 µM ATP (Boehringer Mannheim), and
100 µg/ml histone H2B (Boehringer Mannheim) as a substrate for 20 min
at 30°C. The reactions were terminated with loading buffer.
Phosphorylated histone H2B was viewed by autoradiography.
ERK2 Analysis
CHO stable cell lines were lysed as described for analysis of
AKT activation. Analysis of ERK2 phosphorylation by
immunoblotting was performed with 0.5 µg/ml E10, a
mAb that recognizes ERK2 only when phosphorylated at
Thr202/Tyr204, according to
the manufacturer's instructions (New England Biolabs). ERK2 activation
was analyzed by in vitro kinase assay with myelin basic protein as
described (Fornaro et al., 1999
).
Assay for Detection of Activated Ras
Ras activation was analyzed as described previously (Taylor and
Shalloway, 1996
). Briefly, GST-RBD expression in transformed Escherichia coli DH5
was induced with 1 mM
isopropyl-1-thio-
-D-galactopyranoside (American Bioanalytical) for 2 h at 37°C. The cells were then washed once with ice-cold 20 mM HEPES, pH 7.5, 150 mM NaCl and lysed by
sonication in the following buffer: 20 mM HEPES, pH 7.5, 120 mM NaCl,
10% glycerol, 2 mM EDTA, 100 mg/ml lysozyme (American Bioanalytical),
1 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 µg/ml
pepstatin. The lysate was clarified by centrifugation and incubated
with glutathione Sepharose (Amersham Pharmacia Biotech, Piscataway, NJ)
for 30 min at 4°C. The Sepharose beads were then washed six times
with lysis buffer containing 0.5% NP-40 and stored in the same buffer
at 4°C.
For affinity precipitation, cells were washed twice with ice-cold 20 mM HEPES, pH 7.5, 150 mM NaCl and lysed with the following buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 1% NP-40, 0.25% deoxycholate, 10% glycerol, 10 mM MgCl2, 25 mM sodium fluoride, 1 mM EDTA, 1 mM sodium vanadate, 1 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin) for 30 min at 4°C. One milligram of whole cell lysate was incubated with GST-RBD bound to glutathione Sepharose for 30 min at 4°C. Bound proteins were washed three times with lysis buffer, eluted with loading buffer, and separated by SDS-PAGE (12%). Proteins were visualized by immunoblotting with 2 µg/ml anti-pan Ras mouse mAb according to the manufacturer's instructions (Transduction Laboratories).
Proliferation Assay
CHO stable cell lines were cultured for 48 h either in the absence or in the presence of 1 µg/ml tetracycline, starved during the last 24 h of the 48-h culture, and then detached with 0.05% trypsin/0.53 mM EDTA. Cells were resuspended in serum-free medium and plated (2,500-20,000 cells/well) on either 96- or 24-well plates coated with 1 µg/ml fibronectin for 1 h at 37°C. Attached cells were cultured for 72-96 h at 37°C in growth medium containing 5% FCS either in the absence or in the presence of 1 µg/ml tetracycline. Cells were washed, fixed with 3% paraformaldehyde, and stained overnight with 0.5% toluidine blue. Triplicate observations were performed. Two to 10 fields/well were randomly chosen and counted by microscopic examination. The results are expressed as number of cells per well. Group differences were compared with one-way analysis of variance.
| |
RESULTS |
|---|
|
|
|---|
Analysis of
Subunits Associated with
1C and of
1C-CHO Cell Adhesion
CHO stable cell lines expressing either human
1C or human
1A under
the control of a tetracycline-regulated promoter were characterized for
their ability to associate with
subunits and to adhere to
integrin ligands. Exogenous expression of either
1C or
1A in CHO cells
was analyzed by FACS with TS2/16 mAb to human
1 integrin; comparable levels of
surface expression of
1C and
1A were consistently obtained in all the
experiments 48 h after tetracycline removal (Figure
1, A and B). In parallel, the levels of
endogenous
1 were evaluated in both
1C and
1A CHO stable
cell lines by FACS with 7E2 mAb to hamster
1
integrin (Figure 1, A and B). Exogenous expression of either
1C or
1A was
completely prevented by tetracycline (Figure 1, C and D). The
expression of human
1C and
1A was also analyzed by immunoprecipitation from detergent cell extracts of 125I-labeled CHO
cells. P4C10, a mAb to the human
1
extracellular domain, immunoprecipitated surface-expressed
integrin complexes containing either
1C or
1A (Figure 1E,
lanes 2 and 4). P4C10 immunocomplexes were reprecipitated with rabbit
serum to the
1C cytodomain. These results
confirm appropriate
1C cell surface expression
(Figure 1E, lane 6). To characterize the
subunits associated with
1C, P4C10 immunocomplexes were reprecipitated with rabbit serum against
2,
V, or
5, which are
known to be associated predominantly with
1 in
CHO cells (Takada et al., 1992
; Balzac et al.,
1993
). As shown in Figure 2, both
exogenous
1C and
1A
were associated with endogenous
2,
V, or
5
integrin subunits in CHO stable cell lines. The
1C- and
1A CHO stable cell lines also attached in a comparable manner to increasing concentrations of fibronectin, 7E2, or TS2/16; no differences were
observed in the number of attached cells at 30, 90, or 120 min (Figure
3; our unpublished results).
|
|
|
1C Integrin Expression Does Not Affect FAK
Phosphorylation or AKT Activation
To analyze the effect of
1C on
integrin-mediated intracellular signaling pathways, we used the
CHO stable cell lines described above (Figures 1 and 2). It has been
shown that integrin ligation leads to tyrosine phosphorylation
of intracellular proteins, including FAK (Schwartz et al.,
1995
).
To examine whether FAK phosphorylation was differentially affected by
1C and
1A
integrin variants, FAK was immunoprecipitated from detergent
cell extracts prepared from either
1C or
1A stable cell lines. FAK phosphorylation was
analyzed by immunoblotting with an antibody that
recognizes FAK only when phosphorylated on Tyr397
(Sieg et al., 1999
). As shown in Figure
4, cell adhesion to fibronectin induced
FAK phosphorylation on Tyr397 in both
1C and
1A stable cell
lines compared with cells in suspension (top panel). The results
indicate that
1C integrin expression
does not affect FAK phosphorylation mediated by adhesion to
fibronectin.
|
We then examined the ability of
1C and
1A integrins to activate AKT, a
downstream effector of PI 3-kinase that promotes cell survival. AKT
activity was first assayed on detergent cell extracts obtained from
cells that attached to fibronectin for 10 or 30 min. As shown in Figure
5A, adhesion to fibronectin for 10 min
induced comparable activation of AKT in both
1C and
1A stable cell
lines as determined by in vitro kinase assay (top panel, lanes 2 and
5). However, upon adhesion to fibronectin for 30 min, a modest but
consistent increase of AKT activation was observed in
1C versus
1A stable
cell lines (top panel, lanes 3 and 6). Similar results were obtained by
immunoblotting with a phospho-specific AKT antibody
(Figure 5B); total lysates from cells that were either held in
suspension or allowed to adhere for 30 min to fibronectin, TS2/16, or
7E2 were immunoblotted with phospho-specific antibody to
Ser473. As shown in panel B, a marked increase in
AKT serine phosphorylation was observed in
1C
and
1A stable cell lines upon adhesion to fibronectin (top panel, lanes 2 and 6), 7E2 (top panel, lanes 3 and 7),
or TS2/16 (top panel, lanes 4 and 8) compared with cells in suspension
and with cells on poly-L-lysine (our unpublished results).
These results indicate that both
1 variants
activate AKT in CHO cells. Densitometric analysis performed on three
separate experiments showed that cell adhesion to fibronectin, TS2/16, or 7E2 induced an increase in AKT Ser473
phosphorylation in
1C (6.3 ± 1.4-fold,
4.4 ± 0.8-fold, and 5.5 ± 1.9-fold increase, respectively)
as well as in
1A (2.2 ± 0.5-fold, 2.1 ± 0.2-fold, and 2.7 ± 0.7-fold increase, respectively)
stable cell lines (our unpublished results). No differences in AKT
activation were detected upon adhesion to fibronectin between
1C and
1A stable cell
lines cultured in the presence of tetracycline (Figure 5C, lanes 2, 3, 5, and 6) to prevent expression of exogenous
1 variants. AKT phosphorylation in response to engagement of either endogenous integrins or exogenous
1C
and
1A variants by either fibronectin or
TS2/16 was completely inhibited by wortmannin, a PI 3-kinase inhibitor
(Figure 5B, top panel, lanes 10, 12, 14, and 16). These data show that
1C and
1A do not
differentially affect PI 3-kinase/AKT pathway activation induced by
fibronectin and that antibody-mediated engagement of
1C and
1A stimulates AKT phosphorylation.
|
1C Integrin Expression Inhibits MAP Kinase
Activation Stimulated by Fibronectin
MAP kinase pathway activation by integrins is transient
and is detectable soon after integrin engagement (maximum at 10 min in CHO cells; Figure 6A). We examined
the ability of
1C and
1A to modulate ERK2 activation in CHO stable
cell lines. Endogenous and exogenous integrins were engaged
with fibronectin (Figure 6, A-C), whereas exogenous human
1C or exogenous human
1A integrins were engaged with TS2/16
(Figure 6C). The activation of ERK2 was analyzed by
immunoblotting with E10 mAb, which recognizes the Thr202/Tyr204
phosphorylated form of ERK2 (Figure 6A, top panel), and by in vitro
kinase assay (Figure 6, B and C, top panels); comparable amounts of
ERK2 were used in the kinase assays (Figure 6, B and C, bottom panels).
ERK2 activation was reduced significantly in
1C compared with
1A
stable cell lines in response to integrin engagement by
fibronectin as determined by immunoblotting (Figure 6A,
top panel, lanes 5 and 12) and by in vitro kinase assay (Figure 6, B,
top panel, lanes 9 and 12, and C, top panel, lanes 2 and 5). In the
presence of tetracycline, adhesion to fibronectin mediated by
endogenous integrins induced comparable ERK2 activation in both
1C and
1A stable cell
lines (Figure 6B, top panel, lanes 3 and 6). Exogenous expression of
1 variants in CHO cells did not alter the
expression levels of endogenous hamster
1
subunit or
5
1
integrin as assessed by FACS analysis (Figure 1, A and B; our
unpublished results), indicating that the differences in ERK2
activation on fibronectin between
1C- and
1A-expressing cells were not due to changes in
endogenous
5
1
integrin expression, the major fibronectin receptor in CHO
cells.
|
Ligation of
1C integrin by TS2/16
compared with poly-L-lysine did not induce activation of
ERK2 as assessed by in vitro kinase assay (Figure 6C, top panel, lanes
1 and 3) or by immunoblotting with mAb E10 (our
unpublished results). However, attachment of
1A stable cell lines to TS2/16 resulted in
activation of ERK2 compared with poly-L-lysine (Figure 6C,
top panel, lanes 4 and 6). These results show that
1C has an inhibitory effect on ERK2 activation
mediated by fibronectin and, at variance with
1A, is not able to stimulate ERK2 activity.
These results also show that ERK2 activity is inhibited in cells
attached to fibronectin for 10 min when both FAK and AKT are activated.
1C Integrin Expression Inhibits
Fibronectin-mediated Ras Activation
Several reports have shown the role of Ras as an important
effector of integrin-mediated activation of the MAP kinase
pathway (Schlaepfer et al., 1994
, 1998
; Clark and Hynes,
1996
; Wary et al., 1996
; King et al., 1997
;
Mainiero et al., 1997
; Schlaepfer and Hunter, 1997
; Wei
et al., 1998
). The data presented above indicate that
1C has an inhibitory effect on ERK2 activity.
Therefore, to determine whether
1C mediated
this effect at the level of Ras, Ras activation was assessed through
its ability to bind the Ras-binding domain of Raf-1. This interaction
has been shown to require GTP binding to Ras (Taylor and Shalloway,
1996
). Adhesion of
1A cell transfectants to
fibronectin as well as engagement of endogenous integrins by
fibronectin in
1C stable cell lines cultured
in the presence of tetracycline stimulated Ras activation (Figure
7A, top panel, lanes 1, 2, 9, and 10).
Maximal activation of Ras in CHO cells in the presence of tetracycline
was observed at 10 min (Figure 7A, top panel, lanes 10-12). In
contrast, in the absence of tetracycline,
1C
expression nearly abolished Ras activation mediated by fibronectin
(Figure 7A, top panel, lanes 5-8). We investigated whether Ras could
overcome the
1C inhibitory effect on
fibronectin-mediated ERK2 activation by expressing a constitutively
active form of Ras, Ras 61 (L). Transfection of
1C CHO stable cell lines with constitutively
active Ras 61 (L) restored fibronectin-induced ERK2 activation to the
levels observed in cells transfected with vector alone and cultured in
the presence of tetracycline (Figure 7B, top panel, lanes 4 and 6).
These data indicate that
1C inhibits the MAP
kinase pathway by preventing Ras activation.
|
Inhibition of Cell Proliferation in
1C Transfectants
Is Rescued by MEK
To evaluate whether down-regulation of ERK2 activity causes
inhibition of cell proliferation in
1C
transfectants, we transfected
1C CHO stable
cell lines with either MEK WT or MEK EE. The levels of expression of
both MEK WT and MEK EE were comparable as determined by
immunoblotting with 12CA5 mAb to hemagglutinin (our
unpublished results). As expected,
1C
expression in CHO cells had an inhibitory effect on cell proliferation,
whereas
1A did not affect cell proliferation
in response to serum (Figure 8A).
Transfection of
1C CHO stable cell lines with
MEK EE restored cell proliferation to an extent similar to the level
observed in cells cultured in the presence of tetracycline (Figure 8B).
Thus, expression of constitutively active MEK rescues the inhibitory
effect on cell proliferation exerted by
1C.
|
| |
DISCUSSION |
|---|
|
|
|---|
In this study, as indicated in the model shown in Figure
9, we demonstrate that
1C integrins inhibit ERK2 activation
in response to cell adhesion to fibronectin by preventing Ras
activation. It is also shown that
1C inhibits
Ras and ERK2 activation without affecting either FAK phosphorylation or
AKT activity. Engagement of
1C activates AKT
but is not able to stimulate the MAP kinase pathway; this indicates
that its unique cytodomain allows selective activation of the AKT
kinase pathway in response to engagement of the common
1 extracellular domain. Furthermore,
constitutively active MEK restored cell proliferation in
1C transfectants, suggesting that the negative
effect of
1C on the Ras/ERK pathway causes inhibition of cell proliferation.
|
The aim of this investigation was to determine the roles of two
integrin variants,
1C and
1A, in modulating specific signaling pathways
that control cell proliferation and survival. Specifically, we studied
MAP kinase, FAK, and AKT pathways. MAP kinase pathway involvement in
mediating cell cycle progression and gene expression, as well as the
ability of FAK and AKT to support cell survival and prevent anoikis,
have been well documented (Frisch et al., 1996
; Hungerford
et al., 1996
; Xu et al., 1996
; Khwaja et
al., 1997
; Robinson and Cobb, 1997
; Downward, 1998
; Guadagno and
Ferrell, 1998
; Brunet et al., 1999
; Cary and Guan, 1999
).
The mechanisms of integrin-mediated activation of the MAP
kinase cascade comprise Ras-dependent and Ras-independent activation of
ERK2 by integrins (Howe et al., 1998
). Our results
show that, in contrast to
1A,
1C has an inhibitory effect on Ras and ERK2
activation mediated by fibronectin. Selective inhibition of the Ras/MAP
kinase pathway by
1C indicates that this
integrin has the ability to either interfere with Ras membrane
localization or inhibit positive regulators of Ras, or increase the
activity of negative regulators of this molecule (Rebollo and
Martinez-A, 1999
). FAK has been shown to mediate Ras activation through
Grb2/Sos binding (Schlaepfer and Hunter, 1998
). However, in our system,
we do not expect
1C to act through FAK because
1C inhibits ERK2 activity without affecting integrin signaling to FAK. This is the first description of a selective inhibitory role of the integrin cytoplasmic domain on a member of the MAP kinase family. In one instance, integrin
down-regulation of FAK tyrosine phosphorylation and MAP kinase activity
has been described (Sastry et al., 1999
). Here we show that
FAK phosphorylation and AKT activation can occur in the absence of ERK2
activation, indicating that
1C inhibits either
a pathway downstream of FAK or AKT or a FAK- and AKT-independent
pathway (Figure 9A). It has been described that PI 3-kinase is required
for maximal fibronectin-mediated ERK2 activation and that it functions
downstream of Ras (King et al., 1997
); in our
1C-expressing cells, the PI 3-kinase/AKT pathway is active even though ERK2 is inhibited, suggesting that PI
3-kinase alone is not sufficient to activate ERK2 in the absence of Ras
activation. It was reported recently that PKC inhibition selectively
prevents ERK2 activation in response to integrin without affecting FAK tyrosine phosphorylation (Miranti et al.,
1999
). Thus, expression of
1C might
down-regulate ERK2 activity in response to fibronectin adhesion via
inhibition of PKC, which has been shown to act upstream of Ras (Miranti
et al., 1999
).
The
1C and
1A
variants have a different subcellular distribution (Meredith et
al., 1995
);
1A localizes to focal
contacts, whereas
1C remains diffuse on the
cell surface. Thus, our results indicate that MAP kinase inhibition
observed in
1C transfectants does not require
1C recruitment to focal adhesion complexes. In
a previous report, we had attempted to study ERK2 activation in
response to
1C or
1A
engagement by TS2/16. However, we had not detected either
1C or
1A
integrin-mediated ERK2 activation because of the low
integrin levels and the low number of cells transfected in the
transient expression system (Fornaro et al., 1999
). Here,
using stable cell lines that have higher levels of expression, we show
the failure of
1C to activate ERK2, although we detect MAP kinase activation in response to
1A engagement (Figure 9B). In this study, it
is also shown that AKT phosphorylation is observed in response to
1C engagement (Figure 9B). Therefore, specific
domains in the extreme carboxy-terminal region of
1 are not required to activate the PI
3-kinase/AKT pathway. In our cell system as well as in the cell systems
of others (King et al., 1997
), AKT activation is PI 3-kinase
dependent, because wortmannin completely prevents AKT serine
phosphorylation in response to either endogenous or exogenous
integrin engagement. Ras is a potent activator of PI 3-kinase,
in addition to Raf and non-Raf pathways (Rebollo and Martinez-A, 1999
);
thus, in our experimental system, in which Ras is inhibited,
stimulators of PI 3-kinase different from Ras are expected to be
active. FAK is a potential candidate; PI 3-kinase is activated by FAK
(Chen et al., 1996a
). In our system, a causal effect of FAK
activation on PI 3-kinase/AKT pathway stimulation, in response to
either
1C or
1A
engagement, remains to be investigated. Recent evidence points also to
integrin-linked kinase (ILK) as a candidate effector for
activation of AKT in response to integrin engagement, because
ILK mediates PI 3-kinase-dependent AKT activation and binds the
integrin
1 cytodomain (Hanningan
et al., 1996
; Delcommenne et al., 1998
). However,
ILK binds the integrin
1 cytodomain in
a region that is not found in
1C (S. Dedhar,
personal communication). Thus, although it is crucial for signaling
pathways activated in response to
1A
ligation, ILK is unlikely to play a role in the
activation of AKT in
1C transfectants.
Cell adhesion to fibronectin or to
1 ligands
is unaffected in response to
1C expression.
Furthermore, the
1C variant associates with
the same
subunits as
1A, indicating that
up-regulation of
1C allows the cell to
preserve the interaction with the extracellular matrix but, at the same
time, to inhibit cell cycle progression. Therefore, we suggest that by
expressing v